Effect of wharton's jelly derived-mesenchymal stem cells in treatment of pediatric with cardiomyopathy

Safety Assessment of Intracoronary Transplantation of Wharton's Jelly Derived-Mesenchymal Stem Cells in Pediatric with Non-Ischemic Dilated Cardiomyopathy: Clinical Trial Phase I

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201217049743N1

Enrollment

Registered

2021-01-29

Start date

2021-02-19

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Viral cardiomyopathy. Viral cardiomyopathy

Interventions

Intervention group: Wharton's jelly derived-mesenchymal stem cells receive from a GMP certified bank in Celltech pharmed Co. Then, patients underwent coronary angiography and theses cells which are su

Eligibility

Sex/Gender

All

Age

4 Years to 12 Years

Inclusion criteria

Inclusion criteria: 20% 1 y Candidate for heart transplantation Heart failure due to idiopathic and acute viral myocarditis NYHA function class II/III

Exclusion criteria

Exclusion criteria: Critical aortic stenosis Severe coarctation Coronary artery anomalies Cardiogenic shock

Design outcomes

Primary

Measure	Time frame
Assessment of safety. Timepoint: Base and 1 week, 1,3,6,9 months after transplantation. Method of measurement: Physical examination and clinical symptom.;Assessment of tolerability. Timepoint: Base and 1 week, 1,3,6,9 months after transplantation. Method of measurement: Physical examination and clinical symptom.	—

Secondary

Measure	Time frame
ProBNP measurement. Timepoint: Base, 1, 3, 6, 9 and 12 months after transplantation. Method of measurement: Lab test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHoda Madani

Royan Institute

hoda62_m@yahoo.com+98 21 2251 8388

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026